SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE） — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE） — Stella

Recruiting

Back to Unresectable Locally Recurrent Rectal Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Collaborators

Fudan University, Sun Yat-sen University

Enrollment target

~31 participants

Started

January 2025

Primary completion

November 2026

Age range

18 Years – 75 Years

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov